MY173004A - Mycobacterial antigen vaccine - Google Patents

Mycobacterial antigen vaccine

Info

Publication number
MY173004A
MY173004A MYPI2015000055A MYPI2015000055A MY173004A MY 173004 A MY173004 A MY 173004A MY PI2015000055 A MYPI2015000055 A MY PI2015000055A MY PI2015000055 A MYPI2015000055 A MY PI2015000055A MY 173004 A MY173004 A MY 173004A
Authority
MY
Malaysia
Prior art keywords
combinations
antigens
present
fusion
fusion polypeptides
Prior art date
Application number
MYPI2015000055A
Other languages
English (en)
Inventor
Nathalie Silvestre
Emmanuel Tupin
Romain Micol
Charles Antoine Coupet
Genevieve Inchaupse
Marie Gouanvic
Jean-Baptiste Marchand
Cecile Beny
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of MY173004A publication Critical patent/MY173004A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MYPI2015000055A 2012-07-10 2013-07-10 Mycobacterial antigen vaccine MY173004A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305825 2012-07-10
EP12306539 2012-12-07
EP13305737 2013-06-03

Publications (1)

Publication Number Publication Date
MY173004A true MY173004A (en) 2019-12-18

Family

ID=48782326

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015000055A MY173004A (en) 2012-07-10 2013-07-10 Mycobacterial antigen vaccine

Country Status (16)

Country Link
US (1) US10357555B2 (enExample)
EP (1) EP2872172B1 (enExample)
JP (1) JP6333814B2 (enExample)
KR (1) KR20150058152A (enExample)
CN (1) CN104640564B (enExample)
BR (1) BR112015000530A2 (enExample)
CA (1) CA2878800A1 (enExample)
EA (1) EA029492B1 (enExample)
IL (1) IL236650B (enExample)
MX (1) MX366206B (enExample)
MY (1) MY173004A (enExample)
SG (1) SG11201500171YA (enExample)
TW (1) TWI638829B (enExample)
UA (1) UA119228C2 (enExample)
WO (1) WO2014009438A2 (enExample)
ZA (1) ZA201500784B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357555B2 (en) * 2012-07-10 2019-07-23 Transgene Sa Mycobacterial antigen vaccine
EP3013364B1 (en) * 2013-06-25 2022-08-03 International AIDS Vaccine Initiative, Inc. Tuberculosis compositions and methods of using the same
RU2695462C2 (ru) * 2014-01-09 2019-07-23 Трансген Са Гибридизация гетероолигомерных микобактериальных антигенов
GB201400819D0 (en) * 2014-01-17 2014-03-05 Sec Dep For Health The Mycobacterial antigen composition
US20170056345A1 (en) * 2014-02-18 2017-03-02 Stc.Unm Booster drug therapy for mycobacterium infections
AU2015357225B2 (en) 2014-12-01 2020-04-09 Transgene Sa Stable liquid vaccinia virus formulations
WO2016128542A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
CN105601747B (zh) * 2015-10-21 2019-05-28 中山大学 一种结核杆菌融合蛋白及其在诱导外周血单个核细胞产生细胞因子的应用
KR101631054B1 (ko) * 2015-12-31 2016-06-16 중앙대학교 산학협력단 마이코박테리아 유래 CFP-10 또는 Ag85B에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편
CN105567660B (zh) * 2016-01-08 2018-11-20 中国人民解放军第四军医大学 一种大肠杆菌重组表达结核分枝杆菌Rv2837c活性蛋白的方法及其应用
EP3452081A1 (en) 2016-05-04 2019-03-13 Transgene SA Combination therapy with cpg tlr9 ligand
US20200148729A1 (en) * 2016-05-21 2020-05-14 Infectious Disease Research Institute Compositions and Methods for Treating Secondary Tuberculosis and Nontuberculosis Mycobacterium Infections
WO2017218867A1 (en) * 2016-06-16 2017-12-21 Aeras Tuberculosis compositions and methods of treating or preventing tuberculosis
EP3474889A4 (en) * 2016-06-22 2020-04-29 International AIDS Vaccine Initiative, Inc. RECOMBINANT CYTOMEGALOVIRUS VECTORS FOR USE AS TUBERCULOSIS VACCINES
US11801290B2 (en) 2016-09-16 2023-10-31 Access To Advanced Health Institute Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
CN110291037A (zh) * 2017-02-17 2019-09-27 卫理公会医院 用于确定对象中的感染水平的组合物和方法
CN107236023B (zh) * 2017-05-12 2021-05-07 苏州创澜生物科技有限公司 一种用于检测结核感染的抗原组合物及其应用
WO2019079155A1 (en) 2017-10-17 2019-04-25 International Aids Vaccine Initiative, Inc. CASSETTES OF ANTIGENS OF TUBERCULOSIS
MX2020011298A (es) 2018-04-26 2021-01-29 Childrens Nat Medical Ct Composiciones de antígeno micobacteriano y métodos de uso.
CN109536431A (zh) * 2018-12-04 2019-03-29 江苏省农业科学院 复合生化复苏因子组合物及其应用
KR102135328B1 (ko) * 2018-12-19 2020-07-17 대한민국 결핵 2가 항원을 발현하는 약독화된 재조합 백시니아 바이러스 및 이를 포함하는 결핵 예방용 조성물
KR102157770B1 (ko) * 2019-01-11 2020-09-18 주식회사 파이지노믹스 가축의 결핵 진단을 위한 항원 펩타이드 조성물 및 이의 용도
CN109970183B (zh) * 2019-03-31 2021-01-15 浙江大学 一种复苏促进因子在印染废水处理中的应用及处理方法
PH12021553146A1 (en) * 2019-06-14 2024-04-22 Statens Seruminstitut Fusion proteins for tuberculosis vaccines
CN110590957B (zh) * 2019-09-11 2021-06-01 中国人民解放军总医院第八医学中心 一种融合蛋白及其在抗结核分枝杆菌的免疫保护中的应用
CN110590958B (zh) * 2019-09-11 2021-04-13 中国人民解放军总医院第八医学中心 一种串联多肽及其在抗结核分枝杆菌的免疫保护中的应用
RU2724896C1 (ru) * 2019-11-14 2020-06-26 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Полиантигенная вакцина для профилактики и вспомогательного лечения туберкулеза
CN111443208B (zh) * 2020-03-23 2024-01-19 中国医学科学院北京协和医院 鉴别活动性结核病和潜伏性结核病的组合物
KR20220059111A (ko) * 2020-11-02 2022-05-10 한양대학교 에리카산학협력단 결핵균의 Rv2626c 단백질에서 유래한 패혈증 치료용 펩타이드
CN116262794B (zh) * 2021-12-13 2024-09-13 江苏瑞科生物技术股份有限公司 重组结核分枝杆菌抗原、其制备方法和应用
MA71612A (fr) * 2022-07-29 2025-05-30 University Of Cape Town Constructions de vaccin comprenant des antigènes de tuberculose
WO2024027910A1 (en) * 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
EP4565266A1 (en) * 2022-08-03 2025-06-11 Nanoramic, Inc. Rna for preventing or treating tuberculosis
CN116162141B (zh) * 2022-11-30 2024-04-12 中国疾病预防控制中心传染病预防控制所 一种结核分枝杆菌抗原epcra013及其应用
CN116041543B (zh) * 2022-12-07 2023-12-26 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌多抗原融合蛋白及其编码基因和应用
CN116063418B (zh) * 2022-12-08 2024-04-12 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌抗原组合物epdpa015及其制备方法与应用
WO2025092548A1 (zh) * 2023-11-03 2025-05-08 烟台派诺生物技术有限公司 一种用于预防结核分枝杆菌感染的纳米颗粒疫苗及其制备方法
CN118108815B (zh) * 2024-04-23 2024-07-23 成都康华生物制品股份有限公司 结核分枝杆菌多免疫原抗原、编码其的mRNA、应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
AU672359B2 (en) 1991-03-07 1996-10-03 Virogenetics Corporation Genetically engineered vaccine strain
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
EP0988053A1 (en) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6204026B1 (en) * 1997-11-05 2001-03-20 The Board Of Trustees Of The University Of Arkansas Detection of M. tuberculosis complex via reverse transcriptase SDA
US6892139B2 (en) * 1999-01-29 2005-05-10 The Regents Of The University Of California Determining the functions and interactions of proteins by comparative analysis
ATE332364T1 (de) 1999-02-22 2006-07-15 Transgene Sa Verfahren zur gewinnung von purifizierter virenzuammensetzung
EP1816204B1 (en) 1999-05-17 2010-10-20 Crucell Holland B.V. Recombinant Adenovirus of the Ad26 serotype
DE20122302U1 (de) 2000-11-23 2005-02-24 Bavarian Nordic A/S Variante des Modifizierten Vaccinia-Ankara-Virus
US7393539B2 (en) 2001-06-22 2008-07-01 Health Protection Agency Mycobacterial antigens expressed under low oxygen tension
EP2196473A1 (en) 2001-07-04 2010-06-16 Health Protection Agency Mycobacterial antigens expressed during latency
UA82466C2 (uk) 2001-07-18 2008-04-25 Бавариан Нордика А/С Спосіб посилення ампліфікації хордопоксвірусу
GB0125535D0 (en) 2001-10-24 2001-12-12 Microbiological Res Authority Mycobacterial genes down-regulated during latency
WO2003053463A2 (en) 2001-12-10 2003-07-03 Bavarian Nordic A/S Poxvirus-containing compositions and process for their preparation
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
EP1523331B1 (en) 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
WO2004083418A1 (en) 2003-03-17 2004-09-30 Merck & Co., Inc. Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby
US20040191222A1 (en) 2003-03-28 2004-09-30 Emini Emilio A. Adenovirus serotype 34 vectors, nucleic acids and virus produced thereby
ES2871907T3 (es) 2004-01-23 2021-11-02 Msd Italia Srl Portadores de vacuna de adenovirus de chimpancé
NZ555907A (en) 2004-11-16 2009-12-24 Aeras Global Tb Vaccine Found Multivalent vaccines comprising recombinant viral vectors
MX2007008182A (es) 2005-01-05 2008-02-19 Isis Innovation Composiciones para inmunizar contra micobacteria.
WO2006104389A1 (en) 2005-03-31 2006-10-05 Leiden University Medical Center Methods and means for diagnostics, prevention and treatment of mycobacterium infections and tuberculosis disease
AU2006261445B2 (en) * 2005-06-23 2011-03-31 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
EP1795540A1 (en) * 2005-11-30 2007-06-13 Imaxio Multimeric complexes of antigens and an adjuvant
CN100999550B (zh) * 2006-01-10 2010-10-06 中国人民解放军第三○九医院 结核分枝杆菌融合蛋白及其应用
KR101141333B1 (ko) 2006-06-20 2012-05-23 트랜스진 에스.에이. 재조합 바이러스 백신
EP2368568A1 (en) * 2006-11-01 2011-09-28 Immport Therapeutics, INC. Compositions and methods for immunodominant antigens
MX2009010800A (es) 2007-04-04 2010-01-29 Infectious Disease Res Inst Id Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
TW200844230A (en) 2007-05-15 2008-11-16 Transgene Sa Signaling peptides
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
CN101688182A (zh) 2007-07-03 2010-03-31 特兰斯吉恩股份有限公司 永生化禽细胞系
GB0722105D0 (en) * 2007-11-10 2007-12-19 Sec Dep For Environment Food A Antigens
US7670609B2 (en) * 2007-11-27 2010-03-02 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease
US8361482B2 (en) * 2007-11-27 2013-01-29 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease
GB0906215D0 (en) * 2009-04-09 2009-05-20 Lalvani Ajit Diagnostic test
KR20120026526A (ko) 2009-05-12 2012-03-19 트랜스진 에스.에이. 불멸화 조류 세포주 및 그의 용도
US9610343B2 (en) * 2009-05-20 2017-04-04 Aeras Global Tb Vaccine Foundation Stable, spray dryed, immunogenic, viral compositions
GB0918154D0 (en) * 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
GB201008512D0 (en) * 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
US20130101614A1 (en) * 2010-06-15 2013-04-25 The Regents Of The University Of California Novel live recombinant booster vaccine against tuberculosis
US8771709B2 (en) * 2010-09-20 2014-07-08 Crucell Holland B.V. Therapeutic vaccination against active Tuberculosis
CN103228787B (zh) * 2010-09-28 2017-06-23 阿贝拉生物科学公司 用于分泌性蛋白表达的融合蛋白
WO2012057904A1 (en) 2010-10-27 2012-05-03 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
US20130115240A1 (en) * 2011-11-09 2013-05-09 National Health Research Institutes Recombinant bcg strains with enhanced ability to inhibit intracellular mycobacterial growth
US10357555B2 (en) * 2012-07-10 2019-07-23 Transgene Sa Mycobacterial antigen vaccine
US20150211012A1 (en) * 2012-08-31 2015-07-30 Laboratorios Del Dr. Esteve S.A. Mycobacterium comprising expression vector with two auxotrophic selection markers and its use as vaccine
EP3013364B1 (en) * 2013-06-25 2022-08-03 International AIDS Vaccine Initiative, Inc. Tuberculosis compositions and methods of using the same
TWI654200B (zh) * 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
RU2695462C2 (ru) * 2014-01-09 2019-07-23 Трансген Са Гибридизация гетероолигомерных микобактериальных антигенов
GB201400819D0 (en) * 2014-01-17 2014-03-05 Sec Dep For Health The Mycobacterial antigen composition
JP2017513860A (ja) * 2014-04-24 2017-06-01 スタテンス セールム インスティトゥート 新規結核菌（ｍ．ｔｕｂｅｒｃｕｌｏｓｉｓ）ワクチン
BR112017004576A2 (pt) * 2014-09-09 2018-05-02 Virginia Tech Intellectual Properties Inc vacina multivalente ou composição imunogênica, cepa quimérica de brucella, plasmídeo pns4leub, método para proteger ou tratar um indivíduo em risco de ou que sofre a partir de pelo menos uma doença causada por uma ou mais bactéria, e método de suscitar uma resposta imune tanto para mycobacterium e brucella em um indivíduo
WO2017218867A1 (en) * 2016-06-16 2017-12-21 Aeras Tuberculosis compositions and methods of treating or preventing tuberculosis
EP3474889A4 (en) * 2016-06-22 2020-04-29 International AIDS Vaccine Initiative, Inc. RECOMBINANT CYTOMEGALOVIRUS VECTORS FOR USE AS TUBERCULOSIS VACCINES

Also Published As

Publication number Publication date
BR112015000530A2 (pt) 2018-08-28
HK1207962A1 (en) 2016-02-19
EP2872172A2 (en) 2015-05-20
US10357555B2 (en) 2019-07-23
WO2014009438A3 (en) 2014-04-10
JP6333814B2 (ja) 2018-05-30
US20150165014A1 (en) 2015-06-18
IL236650A0 (en) 2015-02-26
TW201408691A (zh) 2014-03-01
SG11201500171YA (en) 2015-02-27
CA2878800A1 (en) 2014-01-16
MX2015000449A (es) 2015-07-14
IL236650B (en) 2019-09-26
KR20150058152A (ko) 2015-05-28
ZA201500784B (en) 2020-07-29
CN104640564A (zh) 2015-05-20
UA119228C2 (uk) 2019-05-27
JP2015524794A (ja) 2015-08-27
TWI638829B (zh) 2018-10-21
EP2872172B1 (en) 2018-11-14
WO2014009438A2 (en) 2014-01-16
CN104640564B (zh) 2020-08-04
MX366206B (es) 2019-07-02
EA201590184A1 (ru) 2015-06-30
EA029492B1 (ru) 2018-04-30

Similar Documents

Publication Publication Date Title
MY173004A (en) Mycobacterial antigen vaccine
MX2013013111A (es) Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma.
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
WO2015112626A8 (en) Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
WO2013059524A3 (en) Antibodies directed against influenza
PH12017501114A1 (en) Anti-c5 antibodies and methods of use
PH12015500308A1 (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
MX376235B (es) Antígenos asociados a próstata y regímenes de inmunoterapia basados en vacuna.
PH12018501282A1 (en) Anti-c5 antibodies and methods of use
WO2014018858A3 (en) Multimeric fusion protein vaccine and immunotherapeutic
BR112016015936A2 (pt) Combinação imunogênica, molécula de ácido nucleico, vetor, célula hospedeira, método de produção recombinante dos antígenos e composição
EA201500054A1 (ru) Аттенуированные вакцины против streptococcus suis и способы их получения и применения
MX2013007918A (es) Peptidos inmunogenicos monomericos y multimericos.
WO2020065349A8 (en) Vaccines and methods
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
MX353464B (es) Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles.
EP2492689B8 (en) Detection of antibodies using an improved immune complex (IC) ELISA
HK1210475A1 (en) Herpes simplex virus vaccine
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
RU2015106916A (ru) Полипептиды clostridium difficile в виде вакцины
EA201691091A1 (ru) Диагностические реагенты для улучшенной in vivo или in vitro клеточно-опосредованной иммунологической диагностики туберкулеза
BR112017004356A2 (pt) antígenos de streptococcus agalactiae associados a cepas virulentais em peixes
MX374919B (es) ANTÍGENOS Y COMBINACIONES DE ANTÍGENOS PARA USARSE PARA ELEVAR LA RESPUESTA INMUNE CONTRA Haemophilus influenzae.
WO2018066948A3 (ko) 다수의 에피토프로 구성된 재조합 항원 단백질 및 이의 제조방법